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Abstract: 
Liver cirrhosis is highly prevalent in developing countries like Pakistan and osteoporosis is well reported and can 
add to further morbidity in such cases. Objective; To determine the frequency of osteoporosis in cases of liver 
cirrhosis.  
Methods; This cross sectional study was done at outpatient department of RHC Jhawaria, THQ shahpur and RHIC 
Khabeki during July to December 2018. The patients with age 30-70 years having liver cirrhosis of at least 1 year 
or more were included. The detailed sociodemographic and clinical data was collected and osteoporosis was 
labeled as yes when the T score was less than 2.5 on DEXA scan.  
Results; In this study there were total 200 cases out of which 124 (62%) males and 76 (38%) females with mean age 
of 44.35±8.32 years. Osteoporosis was seen in 68 (34%) of cases. Osteoporosis affect more females where it was 
seen in 32 (42.10%) out of 76 cases with p= 0.09. Osteoporosis was significantly high (p=0.002) in cases that had 
cirrhosis more than 3 year affecting 56 (46.67%) cases in contrast to 12 (15%) cases in their respective groups. 
There was no difference regarding type of hepatitis between both groups (table 2).  
Conclusion; Osteoporosis is common in cases of liver cirrhosis where every 3rd cases develops it and duration of 
cirrhosis more than 3 years is significantly associated with this. 
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INTRODUCTION: 
Liver cirrhosis is denoted as the end stage of 
progressive hepatic fibrosis. It is characterized by the 
chronic inflammation, destruction and distortion of 
normal hepatic architecture. This is an irreversible 
condition and liver transplantation is thought to be 
the treatment of choice for this. [1] Liver cirrhosis 
can occur due to various causes and hepatitis B and C 
infection are thought to be the most common ones. 
There are wide range of complications that are seen 
in cases with cirrhosis and include ascites, hepatic 
encephalopathy, gastrointestinal bleeding and 
osteoporosis etc. that can affect and result in 
increased likelihood of morbidity and mortality. [2] 
Osteoporosis is the condition that is the result of 
decreased bone mineral density and it is reported that 
the cases with liver cirrhosis suffer from bone loss at 
much faster rate than the normal cases and it can 
result in complications like easy fractures. The 
estimated prevalence for liver-related osteoporosis is 
between 20-420/100000 of the general population. 
[3] Other risk factors like decreased sun exposure, 
female gender, smoking history, steroid use, diabetes 
mellitus, alcoholism etc also predispose to 
osteoporosis. [4] Furthermore different pathogenic 
mediators like fibronectin, insulin like growth factor-
I, and various cytokines have also been recognized. 
Isolated liver disease to be the cause of osteoporosis 
in the absence of these co factors is highly under 
rated and a neglected entity. However, despite the 
advances in bone biology that have highlighted the 
pathogenesis of this bone loss, treatment options 
remain the same as for osteoporosis due to other 
causes comprising calcium, bisphosphonate and 
vitamin D supplementation. [5-6] Different methods 
have been devised to score for bone mineral density, 
out of which dual energy x-ray absorptiometry 
(DEXA) scan is most commonly used. 
According to a study by Javed M et al osteoporosis 
was seen in 26% of the cases with chronic liver 
disease who had a T score of less than 2.5 on DEXA 
scan. [7] another study conducted by Cijevschi C et 
al in Romania also noted a higher percentage of 
osteopenia and osteoporosis both accounting for 
about 38% of patients with liver cirrhosis. [8] The 
objective of the study was to determine the frequency 
of osteoporosis in patients with liver cirrhosis due to 
hepatitis B and C. 
MATERIALS AND METHODS: 
This cross sectional study was done at outpatient 
department of RHC Jhawaria, THQ shahpur and 
RHIC Khabeki during July to December 2018. The 
200 patients in this study with age range of 30-70 
years having liver cirrhosis (diagnosed clinically with 
presence of ascites, jaundice and shrunken liver on 
USG with increased PT and decreased albumin level) 
of at least 1 year or more due to either hepatitis B or 
C were included. The cases suffering from co morbid 
conditions like DM, metabolic disorders and end 
stage renal or heart disease were excluded. The 
detailed sociodemographic and clinical data was 
collected. Osteoporosis was labeled as yes when the 
T score was less than 2.5 on DEXA scan. 
Statistical analysis:   
Data was analyzed with the help of SPSS version 17. 
Quantitative variables like age, duration of liver 
cirrhosis and value of T score were presented in 
terms of mean ± SD (Standard Deviation). Effect 
modifiers will be controlled through stratification of 
age, gender, duration of liver cirrhosis and type of 
hepatitis to see the effect on outcome variable 
(osteoporosis). Post stratification Chi-Square test was 
applied taking P-value < 0.05 as significant. 
 
RESULTS: 
In this study there were total 200 cases out of which 
124 (62%) males and 76 (38%) females. The mean 
age was 44.35±8.32 years while mean duration of 
CLD was 6.84±2.95 years (table 1). Out of 200, 140 
(70%) cases had HCV positive while 60 (30%) had 
HBV. Osteoporosis was seen in 68 (34%) of cases. 
Osteoporosis affect more females where it was seen 
in 32 (42.10%) out of 76 cases with p= 0.09 and it 
was also more common in age group over 60 years 
affecting 60 (38.71%) cases as compared to 8 
(17.77%) cases with age less than this (p= 0.06). 
Osteoporios was significantly high (p=0.002) in cases 
that had cirhrosi more than 3 year affecting 56 
(46.67%) cases in contrast to 12 (15%) cases in their 
respective groups. There was no difference regarding 
type of hepattis between both groups (table 2).  
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Table 01: Study variables 
 Mean Range 
 
Age 
 
44.35±8.32 
 
30-70 years 
 
Duration of cirrhosis 
 
6.84±2.95 
 
2-15 Years 
 
T score  
 
1.05±0.33 
 
1-4 
 
Figure 1: Frequency of osteoporosis in cases of liver cirrhosis n= 200 
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TABLE 02: Osteoporosis with respect to different variables n= 200 
 
  
Variables 
Osteoporosis   
  Yes No  
 
GENDER 
Male 36 (29.03%) 88 (70.97%)  
p= 0.09 
 Female 32 (42.10%) 44 (57.90%)  
 
AGE GROUPS 
30-50 8 (17.77%) 0 37 (82.22%)  
60-70 60 (38.71%) 95 (61.29%) p= 0.06 
 
DURATION OF 
CIRRHOSIS 
     < 3 years 12 (15%) 68 (85%)  
p= 0.002 
> 3 years 56 (46.67%) 64 (53.33%)  
 
TYPE OF 
HEPATITIS  
Hep B 18 (30%) 42 (70%)  
p= 0.87 Hep C 50 (35.71%) 90 (64.29%) 
 
DISCUSSION: 
Liver cirrhosis poses a great burden in the developing 
countries like Pakistan. Considering the functions of 
liver and the pathophysiology involving various 
mechanisms, these patients are at increased risk of 
decreased bone mineral density and can end up in 
osteopenia and osteoporosis that can further add to 
the overall morbidity and mortality. 
Osteoporosis was seen in 68 (34%) out of 200 cases 
of liver cirrhosis in the present study. In previous 
studies, the incidence of this has been seen from 20 to 
50% of the cases. [9-10] The variation in different 
studies can be due to difference in operational 
definitions to label the osteoporosis and it can also be 
due to difference in site for labeling it ranging form 
femur to vertebral bone. While in a study by Javed M 
et al that used the same criteria as we did with T 
score of less than 2.5, they found osteoporosis in 26% 
of their cases. [7] 
Osteoporosis affected more females where it was 
seen in 32 (42.10%) out of 76 cases with p= 0.09. 
This was also observed by the studies in the past. [11-
12] The higher number of this in females can also be 
due to endocrine factors along with cirrhosis. The 
estrogen and progesterone are deficient in females at 
especially at older age group (due to menopause), 
which was another factor having high osteoporosis 
rate in our study. However this difference was not 
statistically significant. 
Osteoporosis was significantly high (p=0.002) in 
cases that had cirrhosis more than 3 year affecting 56 
(46.67%) cases in contrast to 12 (15%) cases with 
duration less than this in their respective groups. 
Similar has been observed in the past as well where 
the studies by Sokhi RP et al and Javed et al have 
found positive co relation between the duration of 
cirrhosis and the chances of osteoporosis.7,13 In the 
latter above mentioned study they found this  as 
significantly correlated with p value of 0.005; 
however, they used the cut off value of 5 years to 
divide the groups in terms of duration of liver 
cirrhosis.  
CONCLUSION: 
Osteoporosis is common in cases of liver cirrhosis 
where every 3rd cases develops it and duration of 
cirrhosis more than 3 years is significantly associated 
with this. 
 
REFERENCES: 
1. Runyon BA. A primer on detecting cirrhosis 
and caring for these patients without causing 
harm. Int J Hepatol. 2011;2011(1):801-83. 
2. Mumtaz K, Ahmed US, Abid S. Precipitating 
factors and the outcome of hepatic 
encephalopathy in liver cirrhosis. J Coll 
Physicians Surg Pak. 2010;20(8):514-18. 
3. Nakchbandi IA. Osteoporosis and fractures 
in liver disease: relevance, pathogenesis and 
therapeutic implications. World J 
Gastroenterol. 2014;20(28):9427–38. 
4. Jakobsen A, Laurberg P, Vestergaard P, 
Andersen S. Clinical risk factors for osteoporosis 
are common among elderly people in Nuuk, 
Greenland. Int J Circumpolar Health. 
2013;72(8):01-07. 
5. Yadav, A, Carey EJ. Osteoporosis in chronic 
IAJPS 2019, 06 (05), 10027-10031                   Ikram Ellahi et al                     ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 10031 
liver disease. Nutr Clin Pract. 2013;28:12-14. 
6. Kaemmerer D, Schmidt B, Lehmann G, Wolf G, 
Settmacher U, Hommann M. Treatment of bone 
loss in patients with chronic liver disease 
awaiting liver transplantation.  Transplant Res. 
2012;1(1):01-07. 
7. Javed M, Saeed A, Khan IM, Hameed 
K, Rehman S, Khattak AK, et al. Frequency 
of osteoporosis in patients with cirrhosis due 
to hepatitis B and hepatitis C: a study of 100 
cases. J Ayub Med Coll 
Abbottabad. 2009;21(3):51-3. 
8. Cijevschi C, Mihai C, Zbranca E, Gogalniceanu 
P. Osteoporosis in liver cirrhosis. Raomanian J 
Gastroenterol. 2005;14(4):337-41. 
9. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-
Torres M. Bone mineral density, serum insulin 
like growth factor I, and bone turnover markers 
in viral cirrhosis. Hepatology 1998;28:695–9.  
10. Sokhi RP, Anantharaju A, Kondaveeti R, Creech 
SD, Islam KK, Van Thiel DH. Bone mineral 
density among cirrhotic patients awaiting liver 
transplantation. Liver Transpl 2004;10:648–53.  
11. Schiefke I, Fach A, Wiedmann M, Aretin AV, 
Schenker E, Borte G, et al. Reduced bone 
mineral density and altered bone turnover 
markers in patients with non-cirrhotic chronic 
hepatitis B or C infection. World J Gastroenterol 
2005;11:1843–7.  
12. Isoniemi H, Appleberg J, Nilsson CG. 
Transdermal estrogen therapy protects 
postomenopausal liver transplant women from 
osteoporosis. A 2-year follow-up study. J 
Hepatol. 2001;34(2):299-305.  
13. Sokhi RP, Anantharaju A, Kondaveeti R, Creech 
SD, Islam KK, Van Thiel DH. Bone mineral 
density among cirrhotic patients awaiting liver 
transplantation. Liver Transpl 2004;10:648–53.  
